Differential effects of dopamine D1 and D2 agonists and antagonists on velocity of movement, rearing and grooming in the mouse: Implications for the roles of D1 and D2 receptors
References (35)
- et al.
Reduction in motor responding of the mouse by dopamine agonist action in the midbrain
Neuropharmacology
(1983) - et al.
Pharmacological effects of a specific dopamine D-1 antagonist SCH 23390 in comparison with neuroleptics
Life Sci.
(1984) - et al.
Stereotyped behaviour patterns and hyper-activity induced by amphetamine and apomorphine after discrete 6-hydroxydopamine lesions of extrapyramidal and mesolimbic nuclei
Brain Res.
(1977) Dopamine receptors explained
Trends Neurosci.
(1982)- et al.
Activity of two new potent dopaminergic agonists at the striatal and anterior pituitary levels
Neuropharmacology
(1980) - et al.
Sedation and sleep induced by high doses of apomorphine after blockade of D-1 receptors by SCH 23390
Eur. J. Pharmac.
(1985) - et al.
Amphetamine-induced hypolocomotion in mice with more brain D2 dopamine receptors
Psychiat. Res.
(1982) - et al.
The D1 dopamine receptor antagonist SCH 23390 reduces locomotor activity and rearing in rats
Pharmac. Biochem. Behav.
(1985) SCH 23390—the first selective dopamine D-1 antagonist
Eur. J. Pharmac.
(1983)Functional evidence for selective dopamine D-1 receptor blockade by SCH 23390
Neuropharmacology
(1984)
SCH 23390: a selective D1 dopamine antagonist with potent D2 behavioral actions
Eur. J. Pharmac.
Sniffing, rearing and locomotor responses to the D-1 dopamine agonist R-SK & F 38393 and to apomorphine: differential interactions with the selective D-1 and D-2 antagonists SCH 23390 and metoclopramide
Eur. J. Pharmac.
Detailed analysis of the effects of apomorphine and d-Pamphetamine on spontaneous loco-motor behaviour of rats as measured in a TV-based, automated open-field system
Eur. J. Pharmac.
The central effect of a novel dopamine agonist
Eur. J. Pharmac.
Two dopamine receptors: biochemistry, physiology and pharmacology
Life Sci
Electrophysiological, biochemical and behavioral assessment of dopamine autoreceptor activation by a series of dopamine agonists
Eur. J. Pharmac.
Dopamine autoreceptors: pharmacological characterisation by microiontophoretic single cell recording studies
Naunyn-Schmiedebergs Arch. exp. Path. Pharmak.
Cited by (137)
Conditioned catalepsy vs. Increase in locomotor activity induced by haloperidol
2023, Neuroscience LettersEffects of pharmacological inhibition of dopamine receptors on memory load capacity
2019, Behavioural Brain ResearchCitation Excerpt :Animals that did not reach a minimum of 5 s of exploration during the study phase were excluded. This criterion was applied for all doses, except for SCH 23390 0.02 mg/kg in which most of the animals did not reach 5 s of total objects exploration, likely due to its general sedative effects on exploration, which has been previously reported with similar doses [48]. All drugs were purchased from Sigma Aldrich (Milan, Italy).
Ultrasound targeted CNS gene delivery for Parkinson's disease treatment
2017, Journal of Controlled ReleaseCitation Excerpt :To delay potential toxicity induced by l-Dopa, clinicians recommend delaying l-Dopa administration until PD symptoms become clearly obtrusive. Dopamine agonists exert a pharmacologic effect by directly activating dopamine receptors and bypass the pre-synaptic synthesis of dopamine, which has been clinically shown to provide temporary dyskinesia relief due to concurrent activation of D1 and D2 receptors [12,13]. This includes traditional use of dopamine agonists such as bromocriptine and pergolide, or nonergolines modification, and is seen as having lower complications than pramipexole [14] and ropinirole [7].
Effect of subtype-selective adenosine receptor antagonists on basal or haloperidol-regulated striatal function: Studies of exploratory locomotion and c-Fos immunoreactivity in outbred and A<inf>2A</inf>R KO mice
2013, Behavioural Brain ResearchCitation Excerpt :In particular, nucleus accumbens (Nacb) DA has been clearly implicated in the regulation of many forms of exploratory behavior, including spontaneous, novelty-induced, food-induced, and drug-induced locomotion [3–8]. Administration of DA receptor antagonists, including both D1 and D2 selective compounds, decreases a variety of activities [4,9–12]. In contrast, psychostimulant drugs, by potentiating DA transmission, can facilitate behavioral activation [13–16].
Reciprocal interactions between MK-801, sleep deprivation and recovery in modulating rat behaviour
2011, Behavioural Brain ResearchFurther validation of LABORAS™ using various dopaminergic manipulations in mice including MPTP-induced nigro-striatal degeneration
2006, Journal of Neuroscience Methods